Orasis Pharmaceuticals snags $30M to see its presbyopia treatment through to PhIII

Orasis Pharmaceuticals is one of several biotechs developing miotic-based eye drops as a potential alternative to reading glasses — one drop, and no more squinting at text messages. With the help of a $30 million Series C, the Israel-based company has its sights set on Phase III.